Neonatal Screening for Congenital Hypothyroidism in Nicaragua: Audit of a Cord-blood Thyrotropin-based Program (2005-2015)

Funez, Aura; Lara, María Eugenia; Chévez, Ana Cecilia; Castellón, Efrén Alí; Peran, Suzana; Toro, María Josefa Plá del; Montoya, E.; varro, José Carlos Moreno

doi:10.1590/2326-4594-jiems-2019-0003

Cited by 2 publications

(2 citation statements)

References 29 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cord blood NBS program for CH existed until August 2018 when it was discontinued due to the interruption of free testing reagents from the Spanish institutions and the lack of an adequate budget for sustaining the program [ 1251 ]. During the first 10 years, nine additional departments joined the screening effort, involving a total of 12 hospitals [ 1252 ]. In 2014, a pilot expansion that included CH, CAH, PKU, GAL, and BIO was initiated in the Social Security Institute [ 1253 ].…”

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

show abstract

“…Congenital hypothyroidism screening enables timely replacement with thyroxin and efficiently reduces the risk for cognitive defects. 9 This study was conducted to establish the cutoff value of umbilical cord TSH in term neonates for screening CH and correlate cord TSH with birthweight, gender, and gestational age at our study settings.…”

Section: Introductionmentioning

confidence: 99%

Establishing Umbilical Cord Thyroid-stimulating Hormone in Neonates at a Tertiary Care Teaching Hospital for Screening Congenital Hypothyroidism

Padwal¹,

Raichurkar²,

Pore³

et al. 2022

Indian Journal of Medical Biochemistry

View full text Add to dashboard Cite

Aim: To find the normative value of cord thyroid-stimulating hormone (TSH) in neonates in our study group for screening congenital hypothyroidism (CH). Objectives: 1. To establish the cutoff level of cord TSH in full-term and preterm neonates. 2. Correlate cord TSH value with birth weight, gender, and gestational age. Materials and methods: A prospective study was conducted in tertiary care hospital for a period of 1 year from 1st February 2019 to 31st January 2020. Umbilical cord blood (3 mL) collected in sterile vacutainer under aseptic precaution, at the time of delivery from the maternal end of cord and TSH was estimated by chemiluminescent microparticle immunoassay (CMIA) technique. This study was carried out on 1,357 neonates. All data were collected prospectively. Mothers with thyroid illness and/or thyroid medication were excluded from the study. Results: Umbilical cord TSH sample was tested on all 1,357 babies delivered in tertiary hospitals for a period of 1 year. Seven hundred and fifty were males (55.2%) and 607 were females (44.7%). One thousand and sixteen were normal term (74.8%) babies. The mean, median, and standard deviation of cord TSH values were 6.8, 5.5, and 4.5, respectively, in term neonates. Thyroid-stimulating hormone value corresponding to 90th, 95th, and 97th percentile was 16.5, 18.9, and 24.8 percentile in term neonates. Cord TSH values of >20 mIU/L were found in 30 (2.2%) neonates. One neonate had persistently higher TSH on repeat testing. There was no significant correlation of cord TSH between birth weight and gender of neonates but we found a significant correlation of gestational age with cord TSH value (p value < 0.05). Conclusion: Incidence of CH was 1 in 1,357 in our study. Umbilical cord TSH is a significant investigation for screening CH and a cutoff of >20 mIU/L can be used for screening CH.

show abstract

Neonatal Screening for Congenital Hypothyroidism in Nicaragua: Audit of a Cord-blood Thyrotropin-based Program (2005-2015)

Cited by 2 publications

References 29 publications

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Establishing Umbilical Cord Thyroid-stimulating Hormone in Neonates at a Tertiary Care Teaching Hospital for Screening Congenital Hypothyroidism

Contact Info

Product

Resources

About